Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

CMC Strategy for AAV Vectors

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

CMC Strategy for AAV Vectors

CMC Strategy for AAV Vectors: From Process Design to Regulatory Filing in Switzerland

CELL & GENE | RNA | BIOLOGICS

Proven Intelligence in AAV Process Development and Global Regulatory Alignment.

A scientist in a lab coat and gloves looks through a microscope in a laboratory setting, with a blue color overlay.

A scientist pipetting a red liquid into a multi-well plate in a laboratory setting.

Executive Summary

A robust Chemistry, Manufacturing, and Controls (CMC) strategy is the foundation of any successful AAV therapeutic program. For sponsors targeting approvals in Switzerland and the broader European market, this requires a forward-looking approach that anticipates the rigorous demands of Swissmedic and the EMA from the earliest stages of process development. The strategy must encompass scalable vector production, the implementation of phase-appropriate analytical assays, and the generation of a data package sufficient to support a comprehensive Investigational Medicinal Product Dossier (IMPD). Franklin Biolabs integrates these functions, leveraging a >100,000 sq ft facility and the scientific team that achieved a 100% successful IND rate since 2019 to de-risk the path to clinical evaluation. While Franklin Biolabs was formally launched in 2024, this track record reflects the deep institutional history of its founding scientific leadership and core operational teams.

Frequently Asked Questions

How does Franklin Biolabs align AAV CMC strategy with Swissmedic and EMA requirements?

Our approach begins with the regulatory endpoint in mind. We design process development and analytical qualification activities to meet harmonized ICH guidelines, ensuring the data generated for an IMPD submission to Swissmedic or other European authorities is also suitable for a U.S. IND. This includes rigorous characterization of the vector, focusing on identity, purity, potency, and stability.

What is the importance of phase-appropriate analytical development for AAV vectors?

Phase-appropriate analytical development is a core principle for managing program risk and cost. Early-stage research assays are refined and qualified for GxP environments as a program advances. This ensures that the methods used to release clinical trial material are robust, reproducible, and capable of detecting meaningful variations in product quality, a key expectation of regulatory bodies.

Can a platform AAV manufacturing process be adapted for novel or engineered capsids?

Yes. While a platform process provides a validated starting point that accelerates timelines for common serotypes like AAV8 or AAV9, it also serves as a foundation for bespoke optimization. For novel or engineered capsids, key parameters in both upstream (transfection, cell culture) and downstream (purification affinity) processes are systematically adjusted to maximize vector yield and purity.

Foundational Process Development for Regulatory Success

An effective CMC strategy originates in process design. The objective is to establish a manufacturing process that is not only scalable but also consistently produces AAV vectors meeting predefined quality attributes. This transition from a research-scale protocol to a robust, GxP-compliant manufacturing solution is a frequent point of failure for emerging therapeutic programs.

Our scientific teams focus on key process parameters from the outset.

  • Upstream Optimization: Decisions between adherent and AAV scalable suspension platforms are made based on serotype, yield requirements, and long-term commercial goals. We refine variables such as media selection and transfection parameters to enhance vector packaging efficiency.

  • Downstream Purification: The purification train is designed to effectively separate full, active capsids from empty particles and process-related impurities. This directly impacts the final product’s potency and safety profile, which are areas of intense regulatory scrutiny.

A female scientist in a lab coat analyzes complex biological data, including cellular imagery and DNA models, on a computer screen.

A senior scientist with grey hair is mentoring a diverse group of younger scientists or students in a laboratory setting.

A Rigorous, Phase-Appropriate Analytical Framework

A well-defined manufacturing process is meaningless without the analytical tools to verify its output. For Swiss and EU filings, the IMPD must contain a comprehensive analytical package that fully characterizes the AAV vector. This includes a suite of validated assays to assess key quality attributes.

Assay Category Purpose Regulatory Significance
Identity Confirms the correct transgene and capsid. Ensures the correct product is being administered.
Purity Measures empty capsids and process residuals. Directly relates to product safety and immunogenicity.
Quantity/Titer Determines vector genome concentration. Required for accurate dosing in preclinical and clinical studies.
Potency Measures the specific biological activity of the vector. A key indicator of therapeutic efficacy required by all agencies.

This analytical capability, proven in high-profile collaborations such as our work with our partners, ensures that the data package is built on a foundation of scientific rigor, supporting an accelerated 18-24 month timeline to IND.

Navigating Global Regulatory Submissions

A CMC strategy must be global in its design. By adhering to harmonized ICH guidelines, we ensure the data package developed for a Swissmedic submission is largely transferable to other major regulatory bodies. This foresight prevents duplicative work and accelerates global clinical development. The ability to produce sufficient material for IND-enabling studies is a direct output of our work in Large-Scale AAV Manufacturing and Process Development.

The versatility of the AAV platform to deliver complex payloads, such as the multidomain antibodies against influenza described in recent literature (PMID: 30385580), underscores the need for a sophisticated CMC approach. The manufacturing and purification process must be robust enough to accommodate not just the capsid, but also the unique biochemical properties of the expressed transgene product.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities